{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:05:35Z","timestamp":1783044335912,"version":"3.54.6"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Since January 2020, Medicare has covered opioid use disorder (OUD) treatment services at opioid treatment programs (OTPs), the only outpatient settings allowed to dispense methadone for treating OUD. This study examined policy-associated changes in Medicare acceptance and the availability of four OUD treatment services (ongoing buprenorphine, HIV\/AIDS education, employment services, and comprehensive mental health assessment), by for-profit status, and county-level changes in Medicare-accepting-OTPs access, by sociodemographic characteristics (racial composition, poverty rate, and rurality). Using data from the 2019-2022 National Directory of Drug and Alcohol Abuse Treatment Facilities, we found Medicare acceptance increased from 21.31% in 2018 to 80.76% in 2021. The availability of the four treatment services increased, but no increases were significantly associated with Medicare coverage. While county-level OTP access significantly improved, counties with higher rates of non-White residents experienced an additional average increase of 0.86 Medicare-accepting-OTPs (95% CI, 0.05\u20131.67) compared to those without higher rates of non-White populations. Overall, Medicare coverage was associated with improved OTP access, not ancillary services.<\/jats:p>","DOI":"10.1093\/haschl\/qxae076","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T09:34:15Z","timestamp":1717666455000},"source":"Crossref","is-referenced-by-count":10,"title":["Access to treatment before and after Medicare coverage of opioid treatment programs"],"prefix":"10.1093","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0120-6102","authenticated-orcid":false,"given":"Ruijie","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Health Policy and Management, Yale School of Public Health , New Haven, CT 06510 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7746-7459","authenticated-orcid":false,"given":"Tamara","family":"Beetham","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Yale School of Public Health , New Haven, CT 06510 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0989-953X","authenticated-orcid":false,"given":"Helen","family":"Newton","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of North Carolina School of Medicine , Chapel Hill, NC 27599 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-3436","authenticated-orcid":false,"given":"Susan H","family":"Busch","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Yale School of Public Health , New Haven, CT 06510 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"2024062714113520500_qxae076-B1","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2024062714113520500_qxae076-B2","author":"Hedegaard"},{"key":"2024062714113520500_qxae076-B3","author":"House of Representatives, Congress"},{"issue":"3","key":"2024062714113520500_qxae076-B4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/08897077.2020.1787300","article-title":"Medication treatment for opioid use disorder and community pharmacy: expanding care during a national epidemic and global pandemic","volume":"41","author":"Cochran","year":"2020","journal-title":"Subst Abuse"},{"key":"2024062714113520500_qxae076-B5","doi-asserted-by":"crossref","first-page":"108031","DOI":"10.1016\/j.jsat.2020.108031","article-title":"One year of methadone maintenance treatment in a fentanyl endemic area: safety, repeated exposure, retention, and remission","volume":"115","author":"Stone","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"2024062714113520500_qxae076-B6","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/add.16180","article-title":"Polydrug use among patients on methadone medication treatment: evidence from urine drug testing to inform patient safety","volume":"118","author":"Saloner","year":"2023","journal-title":"Addiction"},{"issue":"9","key":"2024062714113520500_qxae076-B7","first-page":"CD011117","article-title":"Opioid agonist treatment for people who are dependent on pharmaceutical opioids","volume":"9","author":"Nielsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2024062714113520500_qxae076-B8","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062714113520500_qxae076-B9","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"4","key":"2024062714113520500_qxae076-B10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamapsychiatry.2022.0004","article-title":"Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic","volume":"79","author":"Friedman","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"2024062714113520500_qxae076-B11","doi-asserted-by":"crossref","first-page":"e2142982","DOI":"10.1001\/jamanetworkopen.2021.42982","article-title":"Disparities by sex and race and ethnicity in death rates due to opioid overdose among adults 55 years or older, 1999 to 2019","volume":"5","author":"Mason","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"19","key":"2024062714113520500_qxae076-B12","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMsa2212412","article-title":"Racial inequality in receipt of medications for opioid use disorder","volume":"388","author":"Barnett","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"2024062714113520500_qxae076-B13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1377\/hlthaff.2020.02261","article-title":"Addressing racial and ethnic disparities in the use of medications for opioid use disorder","volume":"40","author":"Andraka-Christou","year":"2021","journal-title":"Health Aff (Millwood)"},{"key":"2024062714113520500_qxae076-B14","author":"U.S. Department of Health and Human Services, Office of Inspector General"},{"issue":"3","key":"2024062714113520500_qxae076-B15","doi-asserted-by":"crossref","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024062714113520500_qxae076-B16","author":"Electronic Code of Federal Regulations"},{"issue":"2S Suppl 1","key":"2024062714113520500_qxae076-B17","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"J Addict Med"},{"issue":"2","key":"2024062714113520500_qxae076-B18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"J Addict Med"},{"issue":"7","key":"2024062714113520500_qxae076-B19","first-page":"1","article-title":"SAMHSA and FDA move toward medication only for buprenorphine","volume":"25","author":"Knopf","year":"2023","journal-title":"Brown Univ Child Adolesc Psychopharmacol Update"},{"key":"2024062714113520500_qxae076-B20","author":"Centers for Medicare & Medicaid Services"},{"issue":"5","key":"2024062714113520500_qxae076-B21","doi-asserted-by":"crossref","first-page":"e2314328","DOI":"10.1001\/jamanetworkopen.2023.14328","article-title":"Trends in methadone dispensing for opioid use disorder after medicare payment policy changes","volume":"6","author":"Taylor","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2024062714113520500_qxae076-B22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1377\/hlthaff.2023.00148","article-title":"Changes in county-level access to medications for opioid use disorder after Medicare coverage of methadone treatment began","volume":"42","author":"Harris","year":"2023","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"2024062714113520500_qxae076-B23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13011-022-00478-y","article-title":"Medicaid professional fees for treatment of opioid use disorder varied widely across states and were substantially below fees paid by medicare in 2021","volume":"17","author":"Clemans-Cope","year":"2022","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"2024062714113520500_qxae076-B24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/699842","article-title":"Health insurance expansions and providers\u2019 behavior: evidence from substance-use- disorder treatment providers","volume":"61","author":"Maclean","year":"2018","journal-title":"J Law Econ"},{"key":"2024062714113520500_qxae076-B25","author":"Gupta"},{"issue":"24","key":"2024062714113520500_qxae076-B26","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1001\/jama.2023.23147","article-title":"Changes in hospital adverse events and patient outcomes associated with private equity acquisition","volume":"330","author":"Kannan","year":"2023","journal-title":"JAMA"},{"key":"2024062714113520500_qxae076-B27","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2024062714113520500_qxae076-B28","author":"Centers for Medicare & Medicaid Services"},{"key":"2024062714113520500_qxae076-B29","author":"United States Census Bureau"},{"key":"2024062714113520500_qxae076-B30","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"5","key":"2024062714113520500_qxae076-B31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in medicaid","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"2024062714113520500_qxae076-B32","doi-asserted-by":"crossref","first-page":"109092","DOI":"10.1016\/j.drugalcdep.2021.109092","article-title":"National trends in testing for hepatitis C virus in licensed opioid treatment programs: differences by facility ownership and state medicaid expansion status","volume":"228","author":"Pro","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"2024062714113520500_qxae076-B33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MLR.0000000000000121","article-title":"Profiting and providing less care: comprehensive services at for-profit, nonprofit, and public opioid treatment programs in the United States","volume":"52","author":"Bachhuber","year":"2014","journal-title":"Med Care"},{"issue":"24","key":"2024062714113520500_qxae076-B34","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/jama.2013.278456","article-title":"Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs","volume":"310","author":"Bachhuber","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"2024062714113520500_qxae076-B35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1377\/hlthaff.2020.00378","article-title":"Admission practices and cost of care for opioid use disorder at residential addiction treatment programs in the US","volume":"40","author":"Beetham","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"2024062714113520500_qxae076-B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M18-3457","article-title":"Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study","volume":"171","author":"Beetham","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10","key":"2024062714113520500_qxae076-B37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.2021.13197","article-title":"Private equity and health care delivery: value-based payment as a guardrail?","volume":"326","author":"Powers","year":"2021","journal-title":"JAMA"},{"key":"2024062714113520500_qxae076-B38","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"S2","key":"2024062714113520500_qxae076-B39","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The methadone manifesto: treatment experiences and policy recommendations from methadone patient activists","volume":"112","author":"Simon","year":"2022","journal-title":"Am J Public Health"},{"issue":"2","key":"2024062714113520500_qxae076-B40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jamapsychiatry.2013.3575","article-title":"Race\/ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States","volume":"1","author":"Cummings","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"2024062714113520500_qxae076-B41","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2024062714113520500_qxae076-B42","author":"Substance Abuse and Mental Health Services Administration"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxae076\/58120932\/qxae076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/2\/6\/qxae076\/58346889\/qxae076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/2\/6\/qxae076\/58346889\/qxae076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T16:32:21Z","timestamp":1719505941000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxae076\/7688568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxae076","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,30]]},"article-number":"qxae076"}}